Awakn Life Sciences Reports Completing World's First Ketamine Study For A Range Of Behavioral Addictions
SponsoredAwakn's Study On Psychedelics For Treating Addiction Shows Promise, Will Undertake Broader Research
This Biotech Company Is Landing Ketamine-Assisted Therapy In England's Capital
SponsoredAwakn Life Sciences Seeks To Treat Addictions: Gambling, Binge Eating And Compulsive Sexual Behavior
Awakn Life Sciences Recent News
EXCLUSIVE: This Company Hopes to Take an Innovative Approach To Treat Addiction
Sponsored
Psyched: Investment Banks Bullish On Atai Life Sciences, Wesana's $17M Purchase Of PsyTech, Creso Pharma Acquires Halucenex
UK's Awakn Life Sciences Launches Ketamine Research Program For Alcohol And Gambling Addiction
Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies
Awakn Life Sciences: Tackling Britain's Addiction Problems With MDMA and Ketamine
Psyched: German Government Funds Psilocybin Study, Field Trip Opens Psilocybin Clinic